JP2019536438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536438A5 JP2019536438A5 JP2019518299A JP2019518299A JP2019536438A5 JP 2019536438 A5 JP2019536438 A5 JP 2019536438A5 JP 2019518299 A JP2019518299 A JP 2019518299A JP 2019518299 A JP2019518299 A JP 2019518299A JP 2019536438 A5 JP2019536438 A5 JP 2019536438A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- position corresponding
- fusion protein
- alk4
- actriib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022157844A JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404727P | 2016-10-05 | 2016-10-05 | |
| US62/404,727 | 2016-10-05 | ||
| US201762510417P | 2017-05-24 | 2017-05-24 | |
| US62/510,417 | 2017-05-24 | ||
| PCT/US2017/055426 WO2018067879A1 (en) | 2016-10-05 | 2017-10-05 | Alk4:actriib heteromultimers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157844A Division JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536438A JP2019536438A (ja) | 2019-12-19 |
| JP2019536438A5 true JP2019536438A5 (https=) | 2020-11-12 |
| JP7219705B2 JP7219705B2 (ja) | 2023-02-08 |
Family
ID=61831282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518299A Active JP7219705B2 (ja) | 2016-10-05 | 2017-10-05 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| JP2022157844A Pending JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157844A Pending JP2022177286A (ja) | 2016-10-05 | 2022-09-30 | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10934532B2 (https=) |
| EP (1) | EP3522913A4 (https=) |
| JP (2) | JP7219705B2 (https=) |
| KR (1) | KR20190075078A (https=) |
| CN (1) | CN110678195A (https=) |
| AU (1) | AU2017338921A1 (https=) |
| BR (1) | BR112019006993A2 (https=) |
| CA (1) | CA3039573A1 (https=) |
| MA (1) | MA46472A (https=) |
| TW (1) | TW201813978A (https=) |
| WO (1) | WO2018067879A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107849114B (zh) | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| US10227392B2 (en) | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| US11440949B2 (en) | 2016-10-05 | 2022-09-13 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| CA3099325A1 (en) | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | Novel binders of tgf.beta.-superfamily ligands and uses thereof |
| CN111269943B (zh) * | 2019-08-10 | 2023-01-06 | 湖南文理学院 | 一种通过基因敲除技术增加斑马鱼生长速度的方法 |
| EP4073101A4 (en) * | 2019-12-10 | 2024-01-10 | Acceleron Pharma Inc. | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHOD FOR TREATING PULMONARY HYPERTENSION |
| EP4100431A4 (en) * | 2020-02-03 | 2024-10-16 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| WO2021183819A1 (en) * | 2020-03-13 | 2021-09-16 | Acceleron Pharma Inc. | Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
| US20220288226A1 (en) * | 2020-08-27 | 2022-09-15 | Enosi Life Sciences Corp. | Methods and compositions to treat autoimmune diseases and cancer |
| WO2022192420A2 (en) * | 2021-03-10 | 2022-09-15 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
| US20250064952A1 (en) * | 2021-03-10 | 2025-02-27 | Acceleron Pharma Inc. | Actrii-alk4 antagonists and methods of treating heart failure |
| JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
| US20250041385A1 (en) * | 2021-12-10 | 2025-02-06 | Biogen Ma Inc. | Modified actrii proteins and methods of use thereof |
| WO2024238950A1 (en) * | 2023-05-18 | 2024-11-21 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii variants |
| WO2025183964A1 (en) * | 2024-02-27 | 2025-09-04 | Alivegen Usa, Inc | Methods of treating myostatin-related or activin a-related disorders using novel hybrid actriib ligand trap proteins |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US7592428B1 (en) | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| KR950704485A (ko) | 1992-11-17 | 1995-11-20 | 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 | 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use) |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| AU772694B2 (en) | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
| GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| CA2539116C (en) | 2003-09-15 | 2014-11-18 | Research Development Foundation | Cripto antagonism of activin and tgf-b signaling |
| US7833971B2 (en) | 2006-12-08 | 2010-11-16 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2108017A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| ES2449753T3 (es) | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| SMT202300222T1 (it) | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2326670A4 (en) | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY |
| SG10201703067QA (en) | 2008-11-26 | 2017-05-30 | Amgen Inc | Variants Of Activin IIB Receptor Polypeptides And Uses Thereof |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| KR20120108967A (ko) | 2009-09-16 | 2012-10-05 | 제넨테크, 인크. | 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도 |
| FR2951408B1 (fr) | 2009-10-15 | 2012-01-13 | Renault Sa | Cadre moteur pour moteur electrique de vehicule automobile |
| US8999343B2 (en) | 2010-08-16 | 2015-04-07 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| WO2013055809A1 (en) | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| PL2831105T3 (pl) | 2012-03-28 | 2018-01-31 | Univ Texas | Fuzje receptora tgf typu ii - typu iii |
| JP6631865B2 (ja) | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| WO2016090035A2 (en) | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| AU2016238254B2 (en) * | 2015-03-26 | 2022-05-05 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| CN107849114B (zh) | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| US10227392B2 (en) | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| WO2016205370A1 (en) | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| AU2017222526A1 (en) | 2016-02-22 | 2018-08-23 | Acceleron Pharma Inc. | ActRII antagonists for use in increasing immune activity |
| WO2017177013A1 (en) | 2016-04-06 | 2017-10-12 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017293778B2 (en) | 2016-07-07 | 2022-03-24 | Acceleron Pharma Inc. | TGF-beta superfamily heteromultimers and uses thereof |
| WO2018009732A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
-
2017
- 2017-10-05 BR BR112019006993A patent/BR112019006993A2/pt not_active IP Right Cessation
- 2017-10-05 MA MA046472A patent/MA46472A/fr unknown
- 2017-10-05 TW TW106134359A patent/TW201813978A/zh unknown
- 2017-10-05 CA CA3039573A patent/CA3039573A1/en active Pending
- 2017-10-05 US US15/726,255 patent/US10934532B2/en active Active
- 2017-10-05 JP JP2019518299A patent/JP7219705B2/ja active Active
- 2017-10-05 AU AU2017338921A patent/AU2017338921A1/en not_active Abandoned
- 2017-10-05 EP EP17859224.2A patent/EP3522913A4/en active Pending
- 2017-10-05 KR KR1020197012900A patent/KR20190075078A/ko not_active Ceased
- 2017-10-05 CN CN201780075170.8A patent/CN110678195A/zh active Pending
- 2017-10-05 WO PCT/US2017/055426 patent/WO2018067879A1/en not_active Ceased
-
2020
- 2020-12-28 US US17/134,703 patent/US12054753B2/en active Active
-
2022
- 2022-09-30 JP JP2022157844A patent/JP2022177286A/ja active Pending
-
2024
- 2024-06-20 US US18/749,233 patent/US20250084388A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536438A5 (https=) | ||
| JP7101732B2 (ja) | 抗ａｌｋ２抗体 | |
| CN101184776B (zh) | 新型抗胎盘生长因子抗体 | |
| JP2018516240A5 (https=) | ||
| JP2025004103A5 (https=) | ||
| CA2496795C (en) | Compositions and methods for treating cardiovascular disease | |
| JP2019529509A5 (https=) | ||
| JP2022093640A (ja) | 抗ｉｌ－１治療に関する新しい適応症 | |
| TW201813978A (zh) | ＡＬＫ４：ＡｃｔＲＩＩＢ異多聚體及其用途 | |
| JP2011520793A5 (https=) | ||
| JP2014518064A5 (https=) | ||
| KR20190071758A (ko) | 신규한 하이브리드 actriib 리간드 트랩 단백질을 사용한 근육 소모 및 골 질환의 치료 방법 | |
| JP2008106076A (ja) | ＩＩ型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 | |
| JP2007500132A (ja) | Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法 | |
| WO2013023557A1 (zh) | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 | |
| KR20200026789A (ko) | 시누클레인병증을 치료하기 위한 조성물 및 방법 | |
| WO2010019263A2 (en) | Soluble flt constructs for treating cancers | |
| JP2014513941A (ja) | ＦＧＦＲ−Ｆｃ融合蛋白質およびその使用 | |
| EP3169348B1 (en) | Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases | |
| US11208450B2 (en) | GM-CSF variants and methods of use | |
| KR20230111192A (ko) | 액티빈 및 종양괴사인자-알파의 이작용성 길항제 및 이의 용도 | |
| JP2025516361A (ja) | Ｇｌｐ－１と、免疫グロブリンｆｃと、ｉｇｆ－１とを含む融合タンパク質並びにその用途 | |
| WO2025226637A1 (en) | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor | |
| JP6138304B2 (ja) | ＦＧＦＲ−Ｆｃ融合蛋白質およびその使用 | |
| KR20230112629A (ko) | 종양괴사인자-알파 및 형질전환성장인자-베타의 이작용성 길항제 및 이의 용도 |